Antiviral Therapy

Papers
(The median citation count of Antiviral Therapy is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway22
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients22
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ14
Preface: Special Collection Commemorating John C. Martin12
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C12
Real-life findings on the impact of the COVID-19 pandemic on HIV care12
Evaluation of doravirine-based regimen population target in a large Italian clinical center11
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection11
Case study of hepatitis C virus control in Egypt: impact of access program10
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives10
Tenofovir alafenamide fumarate9
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B9
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-198
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case8
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective7
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV7
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)6
Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort6
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study6
Nirmatrelvir treatment duration and frequency of COVID-19 rebound6
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report5
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults4
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir4
The making of the one pill—Developing single tablet regimens for HIV and for HCV4
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection4
Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive t4
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV4
Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor4
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting4
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial4
Adefovir for lamivudine-resistant hepatitis B4
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)–infected patients4
Discovery and development of oseltamivir at Gilead Sciences3
The curing regimens of HCV: A SWOT analysis3
Topical cidofovir for benign human papillomavirus–associated skin lesions3
Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy3
Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark – A national registry study3
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort3
Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation3
A favipiravir-induced angioedema and urticaria in a COVID-19 patient3
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study2
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach2
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants2
Lipid and glucose abnormalities and associated factors among children living with HIV in Asia2
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis2
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation2
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration2
The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B2
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review2
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis2
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts2
Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study2
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report2
Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach2
0.19021391868591